ALEC - NASDAQ

Alector, Inc.

Alector, Inc.

ALECยทNASDAQ

$1.77

-6.1%
HealthcareBiotechnology

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$197.07M
EPS-1.3900
P/E Ratio-1.28
Earnings Date08/06/2026
Alector, Inc.

Alector, Inc. Fair Value Envelope

ALEC ยท NASDAQ

Our analysis suggests that ALEC has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.775, this represents a potential HIDDEN relative to our calculated worth for Alector, Inc..

HIDDEN
Intrinsic Value
Current Price: $1.775

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$3.5B
+ Cash & Equivalents$65.8M
Firm Value-$3.4B
- Debt$36.2M
Equity Value-$3.5B
/ Shares Outstanding101,212,121B
DCF Value-$34
OVERVALUED BY 2035%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$221.5M
-$266.6M
-$321.0M
-$386.3M
-$465.0M
-$559.8M
-$673.8M
-$811.0M
-$976.3M
-$1.2B
Maintenance CapEx
-$9.9K
-$11.9K
-$14.3K
-$17.2K
-$20.7K
-$24.9K
-$30.0K
-$36.1K
-$43.5K
-$52.4K
Owner Earnings
-$221.5M
-$266.7M
-$321.0M
-$386.4M
-$465.1M
-$559.8M
-$673.8M
-$811.1M
-$976.3M
-$1.2B
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$205.1M
-$228.6M
-$254.8M
-$284.0M
-$316.5M
-$352.8M
-$393.2M
-$438.2M
-$488.4M
-$544.3M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your ALEC research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.